Navina

Overview
News
Clinical Decision Support Systems?
Product stageSegments
Go-to-Market
?
Diagnostic support, GenAI-based Clinical Decision Support Systems
?

Navina is an Artificial Intelligence (AI)-powered platform designed to assist primary care physicians by transforming complex patient data into actionable insights at the point of care. The company's proprietary AI technology integrates seamlessly with electronic health records (EHRs) and other data sources, enabling it to interpret structured and unstructured patient information, including clinical notes, lab results, and imaging reports.

Navina's platform generates concise patient portraits that provide physicians with a comprehensive understanding of each patient's health status. These portraits consolidate relevant data from various sources, highlighting potential diagnoses, preventive care measures, and risk factors that require attention. The AI also offers evidence-based recommendations to inform clinical decision-making during patient encounters.

By streamlining access to critical patient information and automating administrative tasks, such as generating progress notes and referral documents, Navina aims to alleviate the documentation burden on physicians, reduce the risk of missed diagnoses, and facilitate more meaningful patient-provider interactions.

Navina's technology has been recognized for its effectiveness in increasing diagnosis accuracy and reducing pre-appointment preparation time by 61%. As of 2024, the platform is utilized by thousands of clinicians across 500 clinics in the US, impacting millions of patients.

In October 2022, Navina raised USD 22 million in a Series B funding round led by ALIVE Israel HealthTech Fund, bringing the total investment raised to USD 44 million. The company plans to use these funds to enhance its AI algorithms, expand data source integrations, and scale its presence among physician groups and healthcare enterprises.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
413 W 14th St, #200, New York, US New York NY USA
Founded year:
2018
Employees:
51-100
IPO status:
Private
Total funding:
USD 44.0 mn
Last Funding:
USD 22.0 mn (Series B; Oct 2022)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.